The FDA announced Thursday it intends to prohibit non-FDA-approved GLP-1 active ingredients. This move threatens to upend the business models of telehealth companies that have built subscription services around affordable access to weight-loss treatments.
In a statement released February 6, 2026, FDA Commissioner Martin A. Makary said the agency would “take decisive steps to restrict GLP-1 active pharm**eutical ingredients intended for use in non-FDA-approved compounded d**gs that are being mass-marketed by companies… as similar alternatives to FDA-approved drugs.”
The announcement comes at a moment when the telehealth sector has solidified its position as a permanent fixture in American healthcare delivery. Virtual care volumes remain approximately 38 times higher than pre-pandemic levels, and platforms have increasingly moved into chronic disease management rather than simple one-off consultations.
Weight management programs built around GLP-1 have become a foundation, with companies offering continuous monitoring, behavioral support, and medication management through subscription models.
While the Trump administration worked to drive down prices for approved GLP-1 through tariff pressure and Most Favored Nation pricing policies, the FDA’s enforcement action suggests a regulatory split over how to balance access with quality control.
The Price Problem That Fueled Compounding
US Secretary of Commerce Howard Lutnick described the pricing dynamics that made compounded alternatives attractive in the first place. Speaking on the All-In Podcast, he outlined how companies charge Americans significantly higher prices than consumers in other countries.
“America is the client, is the consumer, is the payer worldwide,” Lutnick said. “These companies make 75% of their revenues in America, and it’s 100% of their profits.”
He contrasted US pricing with Europe, where Americans often pay around $1,000 for GLP-1s that sell for roughly $175 overseas. According to Lutnick, the disparity stems from how countries with socialized healthcare negotiate.
“Europe says, ‘Yeah, we have socialized medicine. We’re not buying it unless, what’s your cost?’ And the company says 100 bucks. So they say, we’ll pay you $175. You can make 75 bucks,” Lutnick explained.
When companies refuse those terms, governments simply walk away, forcing manufacturers to choose between lower margins or losing the market entirely.
President Donald Trump pushed for a Most Favored Nation pricing model to counter this system.
“Donald Trump says, I want to fix it, and I want MFN price. Most favored nations. So we’re the cheapest price in the world,” Lutnick said. “If you’re willing to sell it to them for 175 bucks, don’t come here and tell me that I have to pay a thousand. It’s just unfair.”
Lutnick said the Commerce Department coordinated with Health and Human Services and Robert F. Kennedy Jr., using tariffs as leverage to force pharmaceutical companies to lower prices and relocate manufacturing operations.
“We want your best product at MFN prices. You can’t sell it to anybody in the world at a better price than you sell to us, of the countries that have money. Charge us the same and reshore, and I’ll waive your tariff while you’re reshoring, provided you do those two, or hammer,” Lutnick said.
He claimed the approach led to sharp price reductions for widely used GLP-1s such as Ozempic and Mounjaro, making them available through Medicaid and Medicare at $149.
“Instead of generally for sale for thousands, everyone in America can have it for 149 bucks,” Lutnick said.
The price gap Lutnick described created the market opportunity that telehealth companies rushed to fill. Platforms offered subscription services, often priced around $139 per month, that included physician consultations and prescriptions for compounded GLP-1 medications. These services targeted patients priced out of brand-name options or denied insurance coverage.
By 2026, roughly 43% of large employers with 5,000 or more employees covered weight-loss medications, with cost frequently cited as the main barrier to broader coverage despite strong employee demand.
Celebrity-Backed Expansion Collides With Regulatory Reality
The growth potential of telehealth weight management attracted high-profile investors and celebrity partnerships.
Tom Brady joined eMed, a digital health startup that pivoted from COVID testing into weight-loss and metabolic health services, as Chief Wellness Officer and board member.
“There are a lot of companies out there, but eMed stood out because they’re building something different; high-quality care, best-in-class service, top practitioners, all focused on prevention and long term health,” Brady said. “That’s what I care about. I want to be part of something that could really help people.”
eMed offers a $139 per month subscription allowing individuals to consult with physicians and receive prescriptions for GLP-1 medications, including a newly launched oral option. The company claims its members show over 90% medication adherence and focuses on helping employers manage the cost of covering weight-loss medications for employees.
Celebrity partnerships have become increasingly common in telehealth marketing, with high-profile athletes including Serena Williams and Charles Barkley involved in GLP-1 or telehealth campaigns.
FDA Draws a Line on Quality Control
The FDA’s announcement makes clear that affordability arguments will not override safety standards. Commissioner Makary stated the actions are “aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.”
“The FDA will use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns,” the statement said. “Entities engaged in the manufacture, distribution, or marketing of unapproved compounded GLP-1 products should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.”
The announcement follows warning letters sent to compounding pharmacies in the fall of 2025, indicating the agency had been building toward enforcement action for months.
The Industry Faces Constraint
Telehealth’s growth depended heavily on regulatory adaptations introduced during and after the pandemic. While not all emergency measures were intended to be permanent, policymakers increasingly moved toward hybrid frameworks that recognized remote care as a standard option rather than an exception.
Federal agencies extended telemedicine flexibilities for prescribing certain medications through December 31, 2026, while permanent rules were still being developed. This created an environment where telehealth companies invested heavily in infrastructure, compliance systems, and clinical operations designed to work under evolving regulations.
By 2026, leading platforms had built flexible care models capable of adjusting to policy changes without collapsing their service offerings. Compliance was treated as an ongoing operational requirement rather than a one-time hurdle.
The FDA’s prohibition lands on a sector that had already transitioned into chronic care delivery at scale. In 2025, the telemedicine sector raised approximately $2.35 billion, a year-over-year increase even amid tighter funding conditions. Investment continued to flow toward platforms that demonstrated operational discipline and sustainable outcomes.
The regulatory action creates tension between two policy goals that have driven healthcare debates throughout the 2020s: ensuring d**g safety and expanding affordable access to treatment.
The Trump administration’s pricing strategy, as described by Lutnick, aimed to force pharmaceutical companies to charge Americans the same prices they charge Europeans. By leveraging tariffs and market access as negotiating tools, the administration claimed it secured dramatic price reductions for approved GLP-1 medications through Medicaid and Medicare.
Yet the FDA’s enforcement action suggests that even with lower prices for approved medications, the agency will not tolerate alternatives that bypass its approval process.
What Comes Next
The FDA’s announcement leaves telehealth companies with limited options. They can pivot to prescribing only approved GLP-1s, which would require patients to pay significantly higher prices even after the administration’s pricing negotiations. They can attempt to build care models around other weight management approaches that don’t rely on GLP-1s. Or they can challenge the FDA’s regulatory interpretation through legal action.
Many platforms had structured their operations around the assumption that compounding pharmacies could legally produce GLP-1 medications when brand-name d**gs were in shortage or when individual patient needs required customized formulations. The FDA’s statement makes clear that mass-marketing compounded versions as alternatives to approved d**gs crosses a regulatory line.
For patients already enrolled in telehealth weight management programs, the prohibition creates immediate uncertainty. Continuity of care will be disrupted for those using compounded medications. Transitioning to approved d**gs may require new insurance authorizations, higher out-of-pocket costs, or gaps in treatment while new prescriptions are processed.
